<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4531042/results/search/test_trace/results.xml">
  <result pre="solid organ transplant and hematopoietic stem cell transplant recipients, cytomegalovirus" exact="infection" post="is associated with high morbidity and preventable mortality. Prevention"/>
  <result pre="is associated with high morbidity and preventable mortality. Prevention and" exact="treatment" post="of cytomegalovirus with currently approved antiviral drugs is often"/>
  <result pre="antiviral drugs that could provide better options for prevention and" exact="treatment" post="of cytomegalovirus. Letermovir (AIC246) is a highly specific antiviral"/>
  <result pre="AIC246 terminase antivirals transplantation Introduction Cytomegalovirus (CMV) is a prevalent" exact="infection" post="that causes significant morbidity and mortality in immunosuppressed patients."/>
  <result pre="morbidity and mortality in immunosuppressed patients. The management of CMV" exact="infection" post="and disease in immunocompromised patients consists of the use"/>
  <result pre="safety and efficacy in humans. Cytomegalovirus, its disease, and its" exact="treatment" post="CMV is the fifth member of the family Herpesviridae1"/>
  <result pre="includes human herpesviruses 6 and 7. CMV is transmitted through" exact="contact" post="with infected body fluid and secretions such as saliva."/>
  <result pre="with infected body fluid and secretions such as saliva. CMV" exact="infection" post="is very common worldwide, with seroprevalence rates that range"/>
  <result pre="the USA,2 to almost 100% in the developing world.3 CMV" exact="infection" post="in healthy individuals is often asymptomatic and generally behaves"/>
  <result pre="such as pneumonitis, enteritis, and rarely, retinitis. In addition, CMV" exact="infection" post="is associated with damaging indirect effects, such as increased"/>
  <result pre="risk of other infections, graft failure, and death.4 Prevention and" exact="treatment" post="of CMV infection and disease after solid organ transplant"/>
  <result pre="infections, graft failure, and death.4 Prevention and treatment of CMV" exact="infection" post="and disease after solid organ transplant and HSCT is"/>
  <result pre="and HSCT is accomplished with use of antiviral drugs. Antiviral" exact="treatment" post="is often complemented by reduction, if feasible, of drug-induced"/>
  <result pre="approved by the US Food and Drug Administration for CMV" exact="treatment" post="are the nucleoside analog GCV, and its valine-ester prod-rug"/>
  <result pre="their use is often associated with adverse effects.5–9 For example," exact="treatment" post="with GCV (and VGCV), which are the workhorses for"/>
  <result pre="that restrict their use as first-line agents for prevention and" exact="treatment" post="of CMV-related disease. Often, transplant patients are receiving other"/>
  <result pre="In October 2010, the drug was used for the compassionate" exact="treatment" post="of a lung transplant patient with CMV disease due"/>
  <result pre="when added as late as up to 57 hours after" exact="infection" post="(compared with only 33 hours for GCV); this is"/>
  <result pre="modified intention-to-treat analysis, the all-cause prophylaxis failure (defined as CMV" exact="infection" post="or study drug discontinuation) was lower in all three"/>
  <result pre="combined failure rate of 29% (P=0.002).42 Virological failure, defined as" exact="detection" post="of CMV DNA during study drug administration, was signifi-cantly"/>
  <result pre="letermovir was given to 27 kidney transplant recipients as pre-emptive" exact="treatment" post="for asymptomatic CMV viral replication that were detected by"/>
  <result pre="load at the end of the 14 days of letermovir" exact="treatment" post="(which is comparable with VGCV). Interestingly, there was a"/>
  <result pre="to letermovir.40 Letermovir was used in a compassionate program for" exact="treatment" post="of severe CMV disease in a lung transplant patient"/>
  <result pre="UL54 mutations). The patient had failed to respond to standard" exact="treatment" post="with GCV, VGCV, PFA, and CDV, off-label treatment with"/>
  <result pre="to standard treatment with GCV, VGCV, PFA, and CDV, off-label" exact="treatment" post="with leflunomide, and compassionate use of CMX-001 (brincidofovir). The"/>
  <result pre="placebo-controlled Phase III clinical trial for the prevention of CMV" exact="infection" post="and disease in allogeneic HSCT recipients. The primary outcome"/>
  <result pre="study is the proportion of participants with clinically significant CMV" exact="infection" post="through week 24 after transplantation. The study is expected"/>
  <result pre="of letermovir Letermovir can potentially be used for prevention and" exact="treatment" post="of CMV infection in transplant recipients. Given the lack"/>
  <result pre="can potentially be used for prevention and treatment of CMV" exact="infection" post="in transplant recipients. Given the lack of hematological side"/>
  <result pre="2 years). Another potential role of letermovir is in the" exact="treatment" post="of active CMV replication, as suggested by the early-phase"/>
  <result pre="early-phase trials and a proof-of-concept trial in kidney recipients. The" exact="treatment" post="of clinically significant CMV disease, in particular of multidrug-resistant"/>
  <result pre="CMV disease, in particular of multidrug-resistant CMV, represents another promising" exact="treatment" post="indication of letermovir. Furthermore, given its lower risk for"/>
  <result pre="the nucleoside analogs as a first-line drug for prevention and" exact="treatment" post="of treatment-naïve CMV disease. One downside for clinical use"/>
  <result pre="appears to be a promising agent for the prevention and" exact="treatment" post="of CMV in transplant recipients. It is highly specific"/>
  <result pre="than GCV. Initial studies indicate its potential for prophylaxis and" exact="treatment" post="of CMV. Its low adverse effect profile makes it"/>
  <result pre="&quot;new kid on the block&quot; for the management of CMV" exact="infection" post="in the vulnerable transplant population. Disclosure The authors report"/>
  <result pre="solid organ transplant recipientsAm J Transplant20044461162015023154 7EinseleHHebartHKauffmann-SchneiderCet al.Risk factors for" exact="treatment" post="failures in patients receiving PCR-based preemptive therapy for CMV"/>
  <result pre="combat cytomegalovirus infections in transplant recipientsCurr Opin Pharmacol20088554154818662804 40StoelbenSArnsWRendersLet al.Preemptive" exact="treatment" post="of cytomegalovirus infection in kidney transplant recipients with letermovir:"/>
  <result pre="in transplant recipientsCurr Opin Pharmacol20088554154818662804 40StoelbenSArnsWRendersLet al.Preemptive treatment of cytomegalovirus" exact="infection" post="in kidney transplant recipients with letermovir: results of a"/>
  <result pre="a Phase 2a studyTranspl Int2014271778624164420 41KaulDRStoelbenSCoberEet al.First report of successful" exact="treatment" post="of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound"/>
  <result pre="in high viral load infections. Lischka et al38 The successful" exact="treatment" post="of a multidrug-resistant CMV infection in a lung transplant"/>
  <result pre="Lischka et al38 The successful treatment of a multidrug-resistant CMV" exact="infection" post="in a lung transplant recipient was reported Kaul et"/>
  <result pre="organ and stem cell transplant recipientsFirst-line or second-line in the" exact="treatment" post="of CMV diseaseTreatment of severe, multidrug-resistant CMV disease Abbreviations:"/>
 </snippets>
</snippetsTree>
